IRCT20220708055414N1 IRCT 2023-02-19 Orchidpharmed Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney Patients SGLT2 I Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney Patients 2022-08-22 anticipated 30 Complete https://irct.ir/trial/64754 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients will be randomly divided into two groups based on whether the last digit of the patient's national code is even or odd, Blinding description: Participant: People who were invited to participate in the study and after full explanations about the design and obtaining informed consent were divided into two intervention and control groups based on whether the national number was even or odd. Researcher: I, who aim to investigate the renoprotective effects of SGLT2 inhibitors on kidney transplant patients, and I am also responsible for collecting data and preparing the draft, without knowing whether the patient's medication box is a drug or a placebo based on the criteria for entering and exiting the box. Medicines were provided to patients. Data analyst: one of the statisticians of the center who analyzes the data according to the numbers of the groups and does not know the control and intervention groups. 3 Condition 1: Diabetes mellitus type 2. Condition 2: Transplant Kidney. Intervention 1: Intervention group: The group that takes Empagloflozin tablets 10 mg daily for 24 weeks. Intervention 2: Control group: The group that takes Plasebo(lactose monohydrate) tablets daily for 24 weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information